Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response : insights from a prospective stud
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
Stereotactic ablative body radiation (SABR) delivers high rates of local control in early-stage non-small cell lung cancer (NSCLC); however, systemic immune effects are poorly understood. Here, we evaluate the early pathologic and immunologic effects of SABR. Blood/core-needle tumor biopsies were collected from six patients with stage I NSCLC before and 5-7 days after SABR (48 Gy/4 or 50 Gy/5 fractions). Serial blood was collected up to 1-year post-SABR. We used immunohistochemistry to evaluate pathological changes, immune-cell populations (CD8, FoxP3), and PD-L1/PD-1 expression within the tumor. We evaluated T-cell receptor (TCR) profile changes in the tumor using TCR sequencing. We used the MANAFEST (Mutation-Associated Neoantigen Functional Expansion of Specific T-cells) assay to detect peripheral neoantigen-specific T-cell responses and dynamics. At a median follow-up of 40 months, 83% of patients (n=5) were alive without tumor progression. Early post-SABR biopsies showed viable tumor and similar distribution of immune-cell populations as compared with baseline samples. Core-needle samples proved insufficient to detect population-level TCR-repertoire changes. Functionally, neoantigen-specific T-cells were detected in the blood prior to SABR. A subset of these patients had a transient increase in the frequency of neoantigen-specific T-cells between 1 week and 3-6 months after SABR. SABR alone could induce a delayed, transient neoantigen-specific T-cell immunologic response in patients with stage I NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 11(2023), 10 vom: 05. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Voong, Khinh Ranh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/jitc-2023-007188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362875766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362875766 | ||
| 003 | DE-627 | ||
| 005 | 20240210232710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2023-007188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM362875766 | ||
| 035 | |a (NLM)37793854 | ||
| 035 | |a (PII)e007188 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voong, Khinh Ranh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response |b insights from a prospective stud |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Stereotactic ablative body radiation (SABR) delivers high rates of local control in early-stage non-small cell lung cancer (NSCLC); however, systemic immune effects are poorly understood. Here, we evaluate the early pathologic and immunologic effects of SABR. Blood/core-needle tumor biopsies were collected from six patients with stage I NSCLC before and 5-7 days after SABR (48 Gy/4 or 50 Gy/5 fractions). Serial blood was collected up to 1-year post-SABR. We used immunohistochemistry to evaluate pathological changes, immune-cell populations (CD8, FoxP3), and PD-L1/PD-1 expression within the tumor. We evaluated T-cell receptor (TCR) profile changes in the tumor using TCR sequencing. We used the MANAFEST (Mutation-Associated Neoantigen Functional Expansion of Specific T-cells) assay to detect peripheral neoantigen-specific T-cell responses and dynamics. At a median follow-up of 40 months, 83% of patients (n=5) were alive without tumor progression. Early post-SABR biopsies showed viable tumor and similar distribution of immune-cell populations as compared with baseline samples. Core-needle samples proved insufficient to detect population-level TCR-repertoire changes. Functionally, neoantigen-specific T-cells were detected in the blood prior to SABR. A subset of these patients had a transient increase in the frequency of neoantigen-specific T-cells between 1 week and 3-6 months after SABR. SABR alone could induce a delayed, transient neoantigen-specific T-cell immunologic response in patients with stage I NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a CD8-positive T-lymphocytes | |
| 650 | 4 | |a adaptive immunity | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a radiotherapy | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Illei, Peter B |e verfasserin |4 aut | |
| 700 | 1 | |a Presson, Bradley |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Dipika |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Lanis, Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Hales, Russell K |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Phuoc T |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiades, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Cheng Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Thiboutout, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Brahmer, Julie R |e verfasserin |4 aut | |
| 700 | 1 | |a Forde, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Naidoo, Jarushka |e verfasserin |4 aut | |
| 700 | 1 | |a Anagnostou, Valsamo |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kellie N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 11(2023), 10 vom: 05. Okt. |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:10 |g day:05 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2023-007188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 10 |b 05 |c 10 | ||